IOmet Pharma Demonstrates Superior in Vivo PK/PD Properties in Pre-Clinical IDO1, TDO and Dual IDO1/TDO Cancer …


IOmet Pharma, a privately-held company focused on cancer immunotherapy and cancer metabolism, will present data demonstrating superior properties of its novel, pre-clinical IDO1, TDO and IDO1/TDO Dual Inhibitor programs. The data will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia on April 22.

IOmet is developing multiple, distinct novel chemical series of potent, IDO1-selective, TDO-selective and dual-acting IDO1/TDO inhibitors. IDO1 (indoleamine-2,3-dioxygenase 1) and TDO (tryptophan-2,3-dioxygenase), the rate-limiting enzymes in the pathway that metabolises the essential amino acid tryptophan, have emerged as key targets for the pharmaceutical industry in the cancer immunotherapy field. Overexpression of these enzymes has been detected in a variety of cancers, including glioma, melanoma, lung, ovarian and colorectal cancers, and is associated with poor prognosis and survival.

IDO1 and TDO overexpression leads to tryptophan depletion and high tumour levels of the breakdown product, kynurenine. This elevated kynurenine/tryptophan (K/T) ratio supresses the body’s immune response to cancer, thus facilitating tumour progression and metastasis. Extensive preclinical evidence, and emerging clinical data, suggests that inhibition of IDO1 and/or TDO may synergise with, and help overcome resistance to, existing clinical cancer therapies, in particular other immunotherapy-based treatments.

Compared to IDO1 and TDO inhibitors identified to date, IOmet’s compounds demonstrate highly favourable in vitro human and rodent PK properties, which translate to superior in vivo PK/PD relationships. Uniquely, IOmet’s programs encompass IDO1-specific, TDO-specific and IDO1/TDO dual inhibitors.

Cancer immunotherapy is an exciting and rapidly growing field of research investigating the use of therapies that harness the body’s own immune system in the fight against cancer. Tumours utilise a variety of mechanisms to evade host immune detection. The aim of the cancer immunotherapy approach is to prevent a tumour’s ability to suppress its own detection and elimination by the patient’s immune system.

About Iomet Pharma

IOmet Pharma Ltd is a privately-held drug discovery company based in Edinburgh, UK. Founded in 2008, IOmet is focused on the development of innovative medicines for the treatment of cancer, with particular emphasis on the fields of cancer immunotherapy and cancer metabolism. IOmet has a team with a proven track record of success in bringing small molecules from discovery phase to the clinic, and is advised by internationally-renowned experts in the fields of cancer immunotherapy (Prof Holbrook Kohrt, Stanford Cancer Institute) and oncology drug development (Dr Rob Williams, Chief Drug Development Scientist, Cancer Research UK (CRUK) and Dr Ian Waddell, Head of Biology, Drug Discovery Unit, CRUK Manchester Institute). For more information, please visit

Source Article from
IOmet Pharma Demonstrates Superior in Vivo PK/PD Properties in Pre-Clinical IDO1, TDO and Dual IDO1/TDO Cancer …
pharma – Yahoo News Search Results
pharma – Yahoo News Search Results


メールアドレスが公開されることはありません。 * が付いている欄は必須項目です

次のHTML タグと属性が使えます: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>